metaPreg - Rizatriptan during pregnancy

Rizatriptan

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.83 [0.48, 1.43]	0%	2 studies	56,797	467	not evaluable	ROB	-
Major congenital malformations	0.72 [0.31, 1.69]	-	1 study	22	310	not evaluable	ROB	-
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Low birth weight (< 2500g)	0.75 [0.37, 1.52]	-	1 study	33	334	not evaluable	ROB	-
Preterm (< 37 weeks)	0.48 [0.26, 0.88]	-	1 study	47	334	not evaluable	ROB	3.63 [.; 1.54]
Small for gestational age (weight)	1.19 [0.69, 2.03]	-	1 study	61	334	not evaluable	ROB	-
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Postpartum hemorrhage	1.11 [0.40, 3.08]	-	1 study	53	26	not evaluable	ROB	-
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	1.58 [0.51, 4.91]	-	1 study	32	26	not evaluable	ROB	-
Hide endpoints reported in only one study ...